Equity Field Notes from temporal sources

[DanWebzster]

CLBS (update)

The meeting with the FDA concerning the late-stage Angina program acquired from Shire will will occur during Q4/18.

Cash runway now only extends thru Q3/19. If FDA requires a pivotal Ph3 Angina trial, a significant capital raise will have to be accomplished.

Meanwhile the Ph2 autologous T-cell treatment for Recent Onset Diabetes is enrolling. Japan has granted this program its breakthrough status.